Abstract
AbstractSevere acute respiratory syndrome coronavirus (SARS-CoV-2) infection leads to the development of coronavirus disease 2019 (COVID-19), which causes endothelial dysfunction (ED), oxidative stress (OS), and inflammatory disorders. These changes cause hypoxia and cytokine storm with the development of cardio-pulmonary complications. Bioactive lipids and other polyunsaturated fatty acids participate in a vital role in the SARS-CoV-2 infection process. One of these mediators is the anti-inflammatory compound, lipoxin (LX). LXs are produced from arachidonic acid (AA) by collaboration between 5-lipoxygenase (5-LO) and 12–15 LO during cell interactions. Thus, our goal was to review the probable role of LXs in COVID-19 regarding the effects of LXs on the inflammatory signaling pathways that are linked with COVID-19 pathogenesis and complications.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference80 articles.
1. Abma W, Noreby M, Wheelock CE, Dahlen SE, Adner M, Säfholm J (2020) Lipoxin A4 reduces house dust mite and TNFα-induced hyperreactivity in the mouse trachea. Prostaglandins Other Lipid Mediat 1(149):106428
2. Ali M, Yang F, Jansen JA, Walboomers XF (2020) Lipoxin suppresses inflammation via the TLR4/MyD88/NF-κB pathway in periodontal ligament cells. Oral Dis 26(2):429–438
3. Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Al-Buhadily AK, Al-Harchan NA, Lugnier C (2020) COVID-19 and phosphodiesterase enzyme type 5 inhibitors. J Microsc Ultrastruct 8(4):141
4. Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Cruz-Martins N, Batiha GE (2021) Sequential doxycycline and colchicine combination therapy in COVID-19: the salutary effects. Pulm Pharmacol Ther 1(67):102008
5. Al-Kuraishy HM, Al-Gareeb AI, Alqarni M, Cruz-Martins N, El-Saber BG (2021) Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Front Pharmacol 23(12):136
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献